Browsing Tag
BSE
157 posts
Wipro FY2026 results: Large deal bookings surge 45%, but constant-currency revenue falls as Q1 FY2027 guidance disappoints
Wipro posts Rs 150B buyback and $7.8B large deal wins but constant-currency revenue falls in FY2026. Q1 FY2027 guidance flat to negative. Read full analysis.
Infosys (INFY) crosses $20bn revenue milestone with $14.9bn large deal TCV as stock tests 52-week lows
Infosys Limited posts $20bn FY26 revenue with $14.9bn large deal TCV. What do the numbers mean for INFY investors and enterprise AI buyers? Read the full analysis.
HCLTECH near 52-week low after Q4 miss — what the FY27 guidance is really telling the market
HCLTech Q4 FY26 results analysed: $620M AI revenue, margin compression, FY27 guidance and what HCLTECH's near 52-week low signals. Read more.
NTPC just hit record capacity additions, signed a nuclear deal with France and still trades at a discount. Worth watching?
NTPC (NSE: NTPC) hit record FY26 capacity additions and signed an EDF nuclear MoU. With ₹380 CMP and analyst targets to ₹440, here is what retail investors need to know.
Wipro (WIT) secures eight-year, $1bn Olam contract and pays $375m for agribusiness IT unit Mindsprint
Wipro secures an $1bn, eight-year Olam Group transformation deal and acquires Mindsprint for $375m. What it means for WIT stock, competitors, and agribusiness IT. Read more.
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Granules India (NSE: GRANULES) exits FDA audit with four observations as regulatory scrutiny intensifies
Granules India's Chantilly facility exits a routine US FDA cGMP audit with four procedural Form 483 observations and no data integrity findings. Read what it means for the GRANULES growth outlook.
K.P. Energy (KPEL) signs IPL deal with Delhi Capitals as stock trades 50% below 52-week high
KP Group's three listed companies join Delhi Capitals as IPL associate sponsors for 2026-2028. What does the strategy mean for KPEL and KPIGREEN? Read more.
Orchid Pharma company profile: business model, financials, and growth outlook (2026 Edition)
Orchid Pharma Limited company profile: cephalosporin API leader, FY2025 revenue Rs. 921.93 Cr, Jammu PLI expansion, novel antibiotic pipeline, and 2026-27 growth outlook.
Dev Information Technology (NSE: DEVIT) to offload ByteSIGNER and Talligence as XDuce partnership reshapes strategic direction
Dev Information Technology transfers ByteSIGNER and Talligence to an associate for Rs 11.90 crore as XDuce's 24% stake signals a bold services-only pivot. Read the full analysis.